NAUT Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. operates as biotech company that develops a platform using computational techniques, cloud computing, AI technologies, and blood tests to detect cancer and potentially other health issues at an early stage. Nautilus Biotechnology, Inc. was formerly known as Ignite Biosciences, Inc. The company was incorporated in 2016 and is based in San Carlos, California.

$2.69  0.00 (0.00%)
As of 07/01/2022 09:40:51 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/07/2020
Outstanding shares:  124,461,653
Average volume:  578,687
Market cap:   $328,578,764
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BNG1NK8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.96
PS ratio:   0.00
Return on equity:   -16.49%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy